Eprosartan + HydrochlorothiazideThird Party Manufacturing in India

Eprosartan + Hydrochlorothiazide is a fixed-dose combination that lowers blood pressure through two complementary mechanisms. Eprosartan is a non-biphenyl, non-tetrazole angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and the adrenal gland. This blockade prevents angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation, reduced peripheral vascular resistance, and decreased blood volume. Unlike ACE inhibitors, eprosartan does not inhibit kininase II and therefore does not affect bradykinin breakdown, resulting in a lower incidence of cough. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the kidney, increasing excretion of sodium, water, and to a lesser extent potassium. The reduction in plasma volume further lowers blood pressure. When used together, eprosartan counteracts the potassium loss caused by hydrochlorothiazide by blocking the renin-angiotensin-aldosterone system, providing a synergistic antihypertensive effect while maintaining electrolyte balance. The combination allows for lower doses of each component with improved efficacy and tolerability.

Therapeutic Uses

Eprosartan + Hydrochlorothiazide is prescribed for the treatment of:

• Essential Hypertension: Indicated for patients whose blood pressure is not adequately controlled on eprosartan or hydrochlorothiazide monotherapy. The combination provides additive blood pressure reduction, often achieving target BP in patients with stage 2 hypertension.
• Hypertension with Volume Overload: Particularly effective in patients who require both vasodilation and diuresis, such as those with salt-sensitive hypertension or mild fluid retention.
• Patients Intolerant to ACE Inhibitors: Eprosartan is a suitable alternative for patients who develop cough or angioedema with ACE inhibitors, while hydrochlorothiazide provides additional BP reduction.

Why Manufacturers Choose Eprosartan + Hydrochlorothiazide

The eprosartan + HCTZ combination is an important product for Indian manufacturers targeting the antihypertensive market, one of the largest therapeutic segments globally. Available as 600 mg/12.5 mg tablets, this combination addresses a significant patient population requiring dual therapy for blood pressure control. Indian contract manufacturing organizations benefit from the established API supply for both eprosartan and hydrochlorothiazide, well-characterized formulation technology, and high-volume demand from both domestic PCD franchises and export markets. This makes Eprosartan + Hydrochlorothiazide one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.